Nagi S. El Saghir, Seock-Ah Im, Hamdy A. Azim, Yesim Eralp, Yoon Sim Yap, Malwinder S. Sandhu, Hikmat Abdel-Razeq, Sudeep Gupta, Elena Artamonova, Julie Rihani, Juan Carlos Mora Payan, Yogesh Chattar, Gary Mark Sopher, Melissa Gao, Yen-Shen Lu. "First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2− advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.1069